1.
|
Phase: Phase IV Type: Prevention, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10-0933, NCT01229319
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 09-1050, 1R21CA156227-01A1, NCT01525329
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SYM 2012-01, NCT01686152
|
|
4.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DCSG 1213, NCT01742663
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: IMQC 1220, NCT01788007
|
|
6.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000582634, P01CA027502, P30CA023074, UARIZ-HSC-04-27, UARIZ-POH-002, HSC #0427, NCT00608634
|
|
7.
|
Phase: Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GESRTAKB, NCT01516515
|
|
8.
|
Phase: No phase specified Type: Treatment Status: Active Age: 18 to 89 Sponsor: Other Protocol IDs: STU68227, NCT01735942
|
|
9.
|
Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2821 50-5, NCT01812837
|